For the Inventor, By the Inventor

Enter assignee name

Kyorin Pharmaceutical Co., Ltd.

USPTO Granted Patents = 185

CIPO Patents = 11

EPO Patents = 42

Forward Citations = 874

Loading Chart...

Loading Chart...

265 inventors (with patents filed for the assignee):

Yasumichi Fukuda (21 out of 21 patents)

Yasushi Kohno (21 out of 21 patents)

Koji Murakami (19 out of 20 patents)

4. Tsutomu Irikura (19 out of 31 patents)

5. Yoshikazu Asahina (14 out of 14 patents)

6. Seigo Suzue (14 out of 16 patents)

7. Katsuya Awano (13 out of 14 patents)

8. Masahiro Nomura (12 out of 23 patents)

9. Kohei Ohata (11 out of 11 patents)

10. Shigeki Seto (10 out of 10 patents)

11. Kazuhiko Kuriyama (9 out of 9 patents)

12. Kuniyoshi Masuzawa (9 out of 9 patents)

13. Keiji Hirai (9 out of 9 patents)

14. Kyuya Okamura (9 out of 9 patents)

15. Takayoshi Ishizaki (9 out of 9 patents)

Core Competencies:

Nucleic Acid Amplification

PCR Reaction Container

15-PGDH Inhibitors

Urea Derivative

Therapeutic Agents

Aqueous Drug Formulations

Solid Pharmaceutical Composition

Cyclopentylacrylamide Derivative

GSK-3 Inhibitors

Indole Derivatives

AMPK Activator Screening

185 patents: Sort by Forward Citations

1. 12357994 - PCR reaction container (2025-07-15),

2. 12351866 - Nucleic acid amplification method (2025-07-08),

3. 12304897 - 15-PGDH inhibitors (2025-05-20),

4. 11952387 - Bicyclic heteroaromatic ring derivative (2024-04-09),

5. 11781181 - Nucleic acid amplification device, nucleic acid amplification method, and chip for nucleic acid amplification (2023-10-10),

6. 11376253 - Agent for treating nocturnal pollakiuria (2022-07-05),

7. 11326163 - Therapeutic agent for fibrosis (2022-05-10),

8. 11261155 - Urea derivative or pharmacologically acceptable salt thereof (2022-03-01),

9. 11098347 - Nucleic acid amplification device, nucleic acid amplification method, and chip for nucleic acid amplification (2021-08-24),

10. 10918634 - Respiratory infection treating agent (2021-02-16),

11. 10858314 - Urea derivative or pharmacologically acceptable salt thereof (2020-12-08),

12. 10696630 - Urea derivative or pharmacologically acceptable salt thereof (2020-06-30),

13. 10617684 - Aqueous drug (2020-04-14),

14. 10525058 - Urea derivative or pharmacologically acceptable salt thereof (2020-01-07),

15. RE47785 - 7-{(3S,4S)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-yl}-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid crystal (2019-12-30),

Kyorin Pharmaceutical Co., Ltd. is a leading Japanese pharmaceutical company, dedicated to improving human health through the development and commercialization of innovative pharmaceutical products. With over 60 years of experience, Kyorin Pharmaceutical is committed to research and development, manufacturing, and marketing of effective drugs and medical solutions. The company focuses on therapeutic areas such as respiratory medicine, otorhinolaryngology, dermatology, urology, and neurology. Kyorin Pharmaceutical aims to contribute to society by providing high-quality medicines that address unmet medical needs and improve patients' quality of life.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

185 Patents

#333 in Tokyo

#727 in Japan

#4,404 in the World

Kyorin Pharmaceutical Co., Ltd.

Forward Citations = 874

265 inventors:

Yasumichi Fukuda (21 out of 21 patents)

Yasushi Kohno (21 out of 21 patents)

Koji Murakami (19 out of 20 patents)

4. Tsutomu Irikura (19 out of 31 patents)

5. Yoshikazu Asahina (14 out of 14 patents)

Please report any incorrect information to support@idiyas.com

Loading…